United States · Platforms & data · Yahoo Finance

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell ...

Published by Yahoo Finance · United States 8 h ago

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

MarketBeat

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

The Motley Fool

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

Seeking Alpha

Musk says Ukraine violated Starlink terms with offensive drone strikes

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

TheStreet

Gold prices break $4,000 as investors brace for crucial test

Benzinga